Bullish Moving Averages
3
Bearish Moving Averages
13
Back Stocks profile
Open Price
5380.00Prev. Close
4928.0500Volume
18335.00Value
96250499.25Market Cap Cr
13123.90
Price to Earnings
94.20
Price to Book Value
22.30
Dividend Yield
0.30
PE to Growth
3.50
Op Revenue TTM Cr
1197.03
Net Profit TTM Cr
139.30
Cash From Operating Activity Cr
58.29
Return on Equity %
16.86
EMA & SMA
Bullish Moving Averages
3
Bearish Moving Averages
13
DELIVERY AND VOLUME
06 May, 2024
Week
Month
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
PIVOT
First Resistance
5494.48
Second Resistance
5569.97
Third Resistance
5640.93
First Support
5348.03
Second Support
5277.07
Third Support
5201.58
Relative Strength Index
54.76
Money Flow Index
30.33
MACD
33.02
MACD Signal
10.39
Average True Range
165.99
Average Directional Index
16.61
Rate of Change (21)
5.2
Rate of Change (125)
16.06
Commodity Channel Index
87.5
Williams %R
-34.8
BETA
1 Month
1.26
3 Month
0.65
1 Year
0.4
3 Year
0.18
PRICE CHANGE ANALYSIS
1 Week
Low
High
5100
5547.95
1 Month
Low
High
5100
5595.85
3 Months
Low
High
4785
6950
6 Months
Low
High
4510
7220.95
1 Year
Low
High
3125
7220.95
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith the certificate dated May 2, 2024 issued by Integrated Registry Management Services Private Limited, RTA of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.Bharat Biotech Asserts Covaxin's Safety Amid AstraZeneca's Rare Side-Effects Admission
Bharat Biotech asserts Covaxin's safety after AstraZeneca's rare side-effects admission, stating it was developed with a focus on safety and efficacy.'Sympathy goes out to anyone who lost loved ones,' says AstraZeneca on Covishield row
The admission came a day after the pharma giant admitted in a UK court that its COVID-19 vaccine sold globally as Covishield and Vaxzevria may cause Thrombocytopenia Syndrome (TTS) in "very rare cases".ASTRAZENECA PHARMA INDIA LTD. - 506820 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyASTRAZENECA PHARMA INDIA LTD. 2CIN NO.L24231KA1979PLC003563 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY 000 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Manasa R Designation: Company Secretary EmailId: manasa.r1@astrazeneca.com Name of the Chief Financial Officer: Bhavana Agrawal Designation: Chief Financial Officer and Director EmailId: bhavana.agrawal@astrazeneca.com Date: 19/04/2024 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.ASTRAZENECA PHARMA INDIA LTD. - 506820 - Certificate Under Regulation 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
As required under Regulation 49(10) of SEBI (LODR) Regulations, 2015, we furnish herewith a certificate issued by the Practising Company Secretary with regard to transfer of securities effected during the year ended March 31, 2024.ASTRAZENECA PHARMA INDIA LTD. - 506820 - Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
This is to certify that Integrated Registry Management Services Private Limited, are the Company''s RTA and that all activities are in relation to the share transfer are maintained by them. We are also attaching the certificate received from our RTA.ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith the Certificate dated April 5, 2024 issued by the RTA of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.ASTRAZENECA PHARMA INDIA LTD. - 506820 - Shareholder Meeting / Postal Ballot-Outcome of Postal Ballot
This is in reference to our letter dated March 6, 2024, enclosing therewith a Postal Ballot Notice dated February 8, 2024 seeking consent of the members of the Company through Special Resolution for appointment of Ms. Bhavana Agrawal (DIN: 10485441) as a Director and also as a Whole-time Director of the Company. In relation to the same, we are enclosing herewith the Voting results along with the Scrutinizer''s Report and the same are being placed on the Company''s website and website of National Securities Depository Limited.AstraZeneca, Daiichi drug gets broad tumor approval in US
The US Food and Drug Administration cleared the medicine for patients who have HER2-positive solid tumors that have spread or can't be removed with surgery, the company said. These patients have already received prior treatment and don't have any good alternatives.The latest market price of AstraZeneca Pharma India Ltd. on NSE was Rs. 5249.55 as of today.
The opening share price of AstraZeneca Pharma India Ltd. was Rs. 5380.00 as of today.
The 52-week high share price of AstraZeneca Pharma India Ltd. was Rs. 7221.00.
The 52 week low share price of AstraZeneca Pharma India Ltd. was Rs. 3125.00.
AstraZeneca Pharma India Ltd. has a market cap of Rs. 13123.90 crore as of today. Please refer to the Fundamentals section for further details.
The PE ratio of AstraZeneca Pharma India Ltd. is 3.50. Please refer to the Fundamentals section for further details.
The operating revenue for AstraZeneca Pharma India Ltd. in the last FY was Rs. 1197.03 crore. Please refer to the Financials section for further details.
The Net Profit for AstraZeneca Pharma India Ltd. in the last FY was Rs. 139.30 crore. Please refer to the Financials section for further details.
Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.
Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.
The latest dividend declared by AstraZeneca Pharma India Ltd. was on 2023-07-14 for Rs. 16 per share. According to today’s share price, the dividend yield of AstraZeneca Pharma India Ltd. stands at 0.30. Please refer to the Corporate Actions section for further details.
The latest split issue declared by AstraZeneca Pharma India Ltd. was as of 2006-06-15. The split ratio declared in this issue was 10:2. Please refer to the Corporate Actions section for further details.
Please refer to Bigul Traders Corner, One Stop destination for different algo and non-algo trading strategies and tools meant for investors, traders, and strategists. Our qualified experts with rich experience in broking, financial analysis, and software development designed it in-house. Click here to learn more.
Please refer to JARVIS, which is Bigul’s AI Portfolio Manager Tool that uses artificial intelligence algorithms to make investment decisions in a portfolio. Click here to learn more.
Please refer to the News section for the latest news about AstraZeneca Pharma India Ltd..